Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

INSMED Inc
Next earnings Aug 5, 2026 · consensus $-0.82 EPS, $397M rev
Last earnings -23.4% on 2026-05-07
Hyper-growth rare-disease pharma with two approved drugs, but $1.28B losses and 34x sales leave no margin for error.
Insmed has crossed from clinical-stage hope into a commercial-stage story, with FY2025 revenue of $606M growing 66.7% year over year on the back of ARIKAYCE and the newly approved BRINSUPRI (brensocatib, approved in the US in August 2025 for non-cystic-fibrosis bronchiectasis). The revenue trajectory is the bull case: from $188M in FY2021 to $606M in FY2025, the top line has more than tripled in four years, and a second commercial product plus EU approval of BRINSUPRI broadens the runway.
Sources: SEC EDGAR (CIK 0001104506, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/21/2026, 8:41:19 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $188M | $245M | $305M | $364M | $606M |
| Gross profit | — | — | — | — | — |
| Operating income | -$375M | -$457M | -$710M | -$878M | -$1.25B |
| Net income | -$435M | -$482M | -$750M | -$914M | -$1.28B |
| Diluted EPS | -$3.88 | -$3.91 | -$5.34 | -$5.57 | -$6.42 |
| Net margin | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1482 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 11 sales
| 2026-06-08 | Lewis William Chair and CEO | Sell | 6.51K @ $94.03 | $613K |
| 2026-06-05 | Flammer Martina M.D. Chief Medical Officer | Sell | 1.86K @ $103.78 | $193K |
| 2026-06-03 | Adsett Roger Chief Operating Officer | Sell | 2.37K @ $102.27 | $242K |
| 2026-06-03 | Bonstein Sara Chief Financial Officer | Sell | 2.40K @ $102.27 | $246K |
| 2026-06-03 | Smith Michael Alexander Chief Legal Officer | Sell | 2.16K @ $102.27 | $221K |
| 2026-06-03 | Lewis William Chair and CEO | Sell | 7.61K @ $102.27 | $778K |
| 2026-06-03 | Flammer Martina M.D. Chief Medical Officer | Sell | 2.57K @ $102.27 | $262K |
| 2026-05-22 | Smith Michael Alexander Chief Legal Officer | Sell | 6.15K @ $108.47 | $667K |
| 2026-05-18 | Lewis William Chair and CEO | Exercise | 6.26K @ $30.46 | $191K |
| 2026-05-18 | Lewis William Chair and CEO | Exercise | 4.44K @ $17.16 | $76.2K |
| 2026-05-18 | Lewis William Chair and CEO | Sell | 5.75K @ $105.32 | $606K |
| 2026-05-18 | Lewis William Chair and CEO | Sell | 11.8K @ $106.39 | $1.26M |